What’s New in CLL?
- Letter Writing Campaign: Urge US Government Officials to Prioritize the Immunocompromised and the Immunosuppressed
- Pandemic Mental Health for the Immunosuppressed
- ASH 2021: Outcomes for Patients with CLL Previously Treated with a Covalent BTK Inhibitor and BCL2 Inhibitor in the United States: A Real-World Database Study
- Idelalisib for Relapsed Follicular Lymphoma (FL) and Small Lymphocytic Leukemia (SLL) Voluntarily Withdrawn from US Market
- ASH 2021: Subcutaneous Epcoritamab in Patients with Relapsed/Refractory CLL: Preliminary Results from the Epcore CLL-1 Trial
- ASH 2021: Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation
Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
CLL Society is an inclusive, patient-centric, physician-curated nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia (CLL) community through patient education, advocacy, support, and research.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. In partnership with Verastem Oncology (Expert Access Founding Supporter), Genentech, and InfiniteMD, the CLL Society is proud to offer this free second opinion program for CLL patients.
We Are in this Together
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL